Related Experiment Video
Updated: Dec 29, 2025

06:51
A Preclinical Murine Model of Hepatic Metastases
Published on: September 27, 2014
30.0K
Preclinical murine tumor models: a structural and functional perspective
Marion V Guerin1, Veronica Finisguerra2, Benoit J Van den Eynde2
1Université de Paris, Institut Cochin, INSERM, U1016, CNRS, UMR8104, F-75014, Paris, France.
Elife
|January 29, 2020
Summary
This review compares murine tumor models, highlighting their weaknesses and why cancer treatments fail in clinics. Understanding tumor microenvironment factors is key for translating preclinical findings to human applications.
Area of Science:
- Oncology
- Translational Medicine
- Cancer Research
Background:
- Murine tumor models are crucial for preclinical cancer research.
- However, treatments effective in these models often fail in clinical settings.
- This discrepancy necessitates a deeper understanding of model limitations.
Purpose of the Study:
- To critically evaluate the strengths and weaknesses of various tumor models.
- To elucidate the reasons behind the poor translation of preclinical findings to clinical success.
- To identify key factors for improving the predictive value of preclinical models.
Main Methods:
- Comparative analysis of transplanted and spontaneous tumor models.
- Focus on structure-function relationships within the tumor microenvironment.
- Examination of factors like vascular architecture and immune cell infiltration.
Main Results:
- Tumor microenvironment features, such as vascularization and epithelial-mesenchymal transition, influence necrosis and immune cell localization.
- Transforming growth factor beta (TGFβ) abundance varies by model, affecting treatment susceptibility.
- Significant differences exist in how models mimic human tumor complexity.
Conclusions:
- Current murine tumor models possess limitations that hinder clinical translation.
- Addressing model-specific factors like tumor microenvironment and TGFβ is essential.
- A historical perspective guides the identification of critical parameters for successful preclinical-to-clinical transitions.

